Coherus Oncology, Inc. Common Stock
Symbol: CHRS (NASDAQ)
1.68
▲ (0.84%) 0.014
Company Description:
Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its strategy is to expand the use of LOQTORZI in NPC and advance the development of new indications for LOQTORZI in combination with both its pipeline candidates as well as its industry partners, driving synergies from proprietary combinations, including first-in-class anticancer agents. Its portfolio includes LOQTORZI, CHS-114, and Casdozokitug.
Key Stats
- Today's Open: $1.7
- Today's High: $1.7
- Today's Low: $1.68
- Today's Volume: 210
- Yesterday Close: $1.67
- Yesterday High: $1.72
- Yesterday Low: $1.65
- Yesterday Volume: 451.63K
- Last Min Volume: 10
- Last Min High: $1.684
- Last Min Low: $1.681
- Last Min VWAP: $1.681
Company Profile
- Name: Coherus Oncology, Inc. Common Stock
- Website: https://www.coherus.com
- Listed Date: 2014-11-06
- Location: REDWOOD CITY, CA
- Market Status: Active
- CIK Number: 0001512762
- SIC Code: 2836
- SIC description: BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
- Market Cap: $202.24M
- Round Lot: 100
- Outstanding Shares: 116.23M
- Asset Type: CS
RECENT FILINGS FOR CHRS
| Filing Date | Filing Type | Format |
|---|---|---|
| 2025-09-08 | 8-K | View |
| 2025-08-07 | 10-Q | View |
| 2025-08-07 | 8-K | View |
| 2025-07-03 | 8-K | View |
| 2025-06-13 | 4 | View |
| 2025-06-13 | 4 | View |
| 2025-06-13 | 4 | View |
| 2025-06-13 | 4 | View |
| 2025-06-13 | 4 | View |
| 2025-06-13 | 4 | View |
| 2025-06-13 | 4 | View |
| 2025-06-13 | 4 | View |
| 2025-06-13 | 8-K | View |
| 2025-05-30 | 8-K | View |
| 2025-05-28 | 4 | View |
| 2025-05-15 | SC TO-I/A | View |
| 2025-05-12 | 10-Q | View |
| 2025-05-12 | 8-K | View |
| 2025-05-09 | 4 | View |
| 2025-05-09 | 4 | View |
Latest News on CHRS